50 research outputs found
Gastric-type adenocarcinoma of the cervix in a patient with Lynch syndrome: A case report
• Lynch syndrome (LS) is an uncommon, genetic disorder which predisposes affected individuals to colorectal, endometrial and ovarian malignancies. • We report a case of cervical gastric-type adenocarcinoma in a patient with LS. • Immunohistochemistry for mismatch repair proteins is a useful screening tool in tumours suspected to be associated with LS
Primary mucinous tumors of the ovary: an interobserver reproducibility and detailed molecular study reveals significant overlap between diagnostic categories
Primary ovarian mucinous tumors represent a heterogeneous group of neoplasms, and their diagnosis may be challenging. We analyzed 124 primary ovarian mucinous tumors originally diagnosed as mucinous borderline tumors (MBTs) or mucinous carcinomas (MCs), with an emphasis on interobserver diagnostic agreement and the potential for diagnostic support by molecular profiling using a next-generation sequencing targeted panel of 727 DNA and 147 RNA genes. Fourteen experienced pathologists independently assigned a diagnosis from preset options, based on a review of a single digitized slide from each tumor. After excluding 1 outlier participant, there was a moderate agreement in diagnosing the 124 cases when divided into 3 categories (κ = 0.524, for mucinous cystadenoma vs MBT vs MC). A perfect agreement for the distinction between mucinous cystadenoma/MBT as a combined category and MC was found in only 36.3% of the cases. Differentiating between MBTs and MCs with expansile invasion was particularly problematic. After a reclassification of the tumors into near-consensus diagnostic categories on the basis of the initial participant results, a comparison of molecular findings between the MBT and MC groups did not show major and unequivocal differences between MBTs and MCs or between MCs with expansile vs infiltrative pattern of invasion. In contrast, HER2 overexpression or amplification was found only in 5.3% of MBTs and in 35.3% of all MCs and in 45% of MCs with expansile invasion. Overall, HER2 alterations, including mutations, were found in 42.2% of MCs. KRAS mutations were found in 65.5% and PIK3CA mutations in 6% of MCs. In summary, although the diagnostic criteria are well-described, diagnostic agreement among our large group of experienced gynecologic pathologists was only moderate. Diagnostic categories showed a molecular overlap. Nonetheless, molecular profiling may prove to be therapeutically beneficial in advanced-stage, recurrent, or metastatic MCs. MTG8 - Moleculaire pathologie van gynecologische tumorenMolecular tumour pathology - and tumour genetic
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform classification framework for NENs at any anatomical location may reduce inconsistencies and contradictions among the various systems currently in use. The classification suggested here is intended to allow pathologists and clinicians to manage their patients with NENs consistently, while acknowledging organ-specific differences in classification criteria, tumor biology, and prognostic factors. The classification suggested is based on a consensus conference held at the International Agency for Research on Cancer (IARC) in November 2017 and subsequent discussion with additional experts. The key feature of the new classification is a distinction between differentiated neuroendocrine tumors (NETs), also designated carcinoid tumors in some systems, and poorly differentiated NECs, as they both share common expression of neuroendocrine markers. This dichotomous morphological subdivision into NETs and NECs is supported by genetic evidence at specific anatomic sites as well as clinical, epidemiologic, histologic, and prognostic differences. In many organ systems, NETs are graded as G1, G2, or G3 based on mitotic count and/or Ki-67 labeling index, and/or the presence of necrosis; NECs are considered high grade by definition. We believe this conceptual approach can form the basis for the next generation of NEN classifications and will allow more consistent taxonomy to understand how neoplasms from different organ systems inter-relate clinically and genetically
Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data
Ovarian carcinoma is the most lethal
gynaecological malignancy, most tumours being
advanced at presentation. However, little is known about
precursor lesions and the cell of origin of epithelial
ovarian malignancy. In this review, the proposed cell of
origin is discussed as well as recent molecular data
relating to ovarian cancers of different morphological
types. It is stressed that ovarian carcinoma is a
heterogeneous group of neoplasms with several different
morphological types, each with their own underlying
molecular genetic events. Recent data suggest that
mucinous ovarian cancers and a small subset of serous
cancers (low grade ovarian serous carcinoma) develop
through a well-defined adenoma-carcinoma sequence
while the much more common high grade ovarian serous
carcinoma develops de novo from the ovarian surface
epithelium or the epithelium of cortical inclusion cysts.
The realisation that various morphological types of
epithelial ovarian cancer are associated with different
molecular genetic events is a major advance in the study
of ovarian cancer. It can be anticipated that this will lead
to the development of specific therapeutic agents of
value against a specific tumour type
Incorporating molecular profiling into endometrial cancer management requires prospective studies
Item does not contain fulltex